Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

被引:6
作者
Frantz, Robert P. [1 ]
Chin, Kelly M. [2 ]
Zhao, Carol [3 ]
Flynn, Megan [3 ]
Badesch, David [4 ]
机构
[1] Mayo Clin, Dept Cardiovasc Dis, Coll Med, Rochester, MN 55905 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Pulm Hypertens Program, Internal Med, Dallas, TX 75390 USA
[3] Actel Pharmaceut US Inc, San Francisco, CA USA
[4] Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO USA
关键词
pulmonary arterial hypertension; patient-reported outcomes; symptoms; clinical practice; QUALITY-OF-LIFE; OUTCOME MEASURES;
D O I
10.1177/2045894020923957
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patient-reported outcomes are important measures to include in pulmonary arterial hypertension clinical trials but are not widely utilized in clinical practice. Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire (PAH-SYMPACT) is the only pulmonary arterial hypertension-specific patient-reported outcomes instrument developed and validated in accordance with the US Food and Drug Administration guidance on patient-reported outcomes development. The PAH-SYMPACT tool measures pulmonary arterial hypertension-related symptoms and impact of pulmonary arterial hypertension on daily life. Symptoms are reported each day for seven consecutive days, and the impact of pulmonary arterial hypertension over one week is recalled and reported on day 7; however, daily symptom reporting may overburden patients and healthcare resources, limiting the practicality of PAH-SYMPACT outside of clinical trials. To determine the practicability of an abridged version of PAH-SYMPACT for which all reporting is completed on one day, symptom data from the SYMPHONY trial (NCT01841762; PAH-SYMPACT validation study) were retrospectively analyzed to assess whether symptoms reported on each day correlated with the weekly average and whether one-day symptom scores were sensitive to disease severity. Correlation coefficients comparing the weekly average and individual day symptom scores were mostly high or very high regardless of the day they were measured. Findings were similar when using either Spearman's rank correlation or weighted kappa method. One-day symptom scores differentiated well between World Health Organization functional classes II and III/IV pulmonary arterial hypertension and were sensitive to change in disease severity as measured by the Patient Global Assessment of Disease Severity. These data suggest that the one-day PAH-SYMPACT is feasible and appropriate for routine implementation in clinical practice.
引用
收藏
页数:9
相关论文
共 31 条
[1]  
Aaronson N., User's guide to implementing patient-reported outcomes assessment in clinical practice
[2]  
[Anonymous], J AM COLL CARDIOL
[3]  
[Anonymous], 2014, Cochrane handbook for systematic reviews of interventions version 5.1.0
[4]  
[Anonymous], 2009, J AM COLL CARDIOL, DOI DOI 10.1016/j.jacc.2009.04.012
[5]   Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients [J].
Bonner, Nicola ;
Abetz, Linda ;
Meunier, Juliette ;
Sikirica, Mirko ;
Mathai, Stephen C. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
[6]  
Chen Hubert, 2008, Proc Am Thorac Soc, V5, P623, DOI 10.1513/pats.200802-020SK
[7]   Psychometric Validation of the Pulmonary Arterial Hypertension- Symptoms and Impact (PAH-SYMPACT) Questionnaire Results of the SYMPHONY Trial [J].
Chin, Kelly M. ;
Gomberg-Maitland, Mardi ;
Channick, Richard N. ;
Cuttica, Michael J. ;
Fischer, Aryeh ;
Frantz, Robert P. ;
Hunsche, Elke ;
Kleinman, Leah ;
McConnell, John W. ;
McLaughlin, Vallerie V. ;
Miller, Chad E. ;
Zamanian, Roham T. ;
Zastrow, Michael S. ;
Badesch, David B. .
CHEST, 2018, 154 (04) :848-861
[8]   Pulmonary arterial hypertension: the burden of disease and impact on quality of life [J].
Delcroix, Marion ;
Howard, Luke .
EUROPEAN RESPIRATORY REVIEW, 2015, 24 (138) :621-629
[9]   Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006-2010) [J].
DeMuro, Carla ;
Clark, Marci ;
Doward, Lynda ;
Evans, Emily ;
Mordin, Margaret ;
Gnanasakthy, Ari .
VALUE IN HEALTH, 2013, 16 (08) :1150-1155
[10]   2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension [J].
Galie, Nazzareno ;
Humbert, Marc ;
Vachiery, Jean-Luc ;
Gibbs, Simon ;
Lang, Irene ;
Torbicki, Adam ;
Simonneau, Gerald ;
Peacock, Andrew ;
Noordegraaf, Anton Vonk ;
Beghetti, Maurice ;
Ghofrani, Ardeschir ;
Sanchez, Miguel Angel Gomez ;
Hansmann, Georg ;
Klepetko, Walter ;
Lancellotti, Patrizio ;
Matucci, Marco ;
McDonagh, Theresa ;
Pierard, Luc A. ;
Trindade, Pedro T. ;
Zompatori, Maurizio ;
Hoeper, Marius .
REVISTA ESPANOLA DE CARDIOLOGIA, 2016, 69 (02) :177-177